NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/26/2026 16:00
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,042.24 mln
Float114 mln
Earnings Date08/19/2026
EPS
0.10
Overpriced
P / E
34.20
Overvalued
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-3.18
Reliable
1-Year Forecast
13.83
Transformational upside
Relative Strength
19
/ 100
Significantly lagging
Business Description
Founded in 2013 and headquartered in Luxembourg, Alvotech develops and manufactures biosimilar medicines designed to be more affordable alternatives to established biologic drugs. The company's portfolio targets a range of serious conditions, including inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis, as well as eye conditions, bone disorders, certain cancers, and respiratory allergies. Alvotech supplies these medicines to patients across the world through its subsidiaries and commercial partners.
